Vir Biotech Chair Sells Shares, No Insider Trading

Vir Biotechnologys board chair, Vicki Sato, recently sold 22,000 shares, worth $221,000, following a pre-planned Rule 10b5-1 trading plan. Despite this, she still holds over 1.78 million shares, valued at approximately $10.78 million. The stock has been on an upward trend, reaching a 52-week high of $11.66 on April 20th, due to positive early trial data on treatments for challenging diseases. The company is developing immunology therapies for viruses like COVID, hepatitis B, flu, and HIV, generating revenue through sales, licenses, and partnerships. With a market cap of $1.57 billion and $809 million in cash, Vir is well-positioned to advance its trials and approvals. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bc92b736a575de64